Globus Medical (NYSE: GMED) saw its stock price surge 5.23% in after-hours trading on Thursday following the release of its second quarter 2025 financial results, which exceeded analyst expectations.

The medical device company reported Q2 adjusted earnings per share of $0.86, significantly beating the analyst consensus estimate of $0.76. This represents a 14.67% increase from $0.75 per share in the same period last year. Globus Medical's quarterly sales also outperformed, reaching $745.342 million, surpassing the analyst estimate of $738.903 million and marking an 18.37% year-over-year increase from $629.691 million.

Investors were particularly encouraged by Globus Medical's reaffirmation of its full-year 2025 guidance. The company maintained its revenue outlook of $2.80 billion to $2.90 billion and non-GAAP EPS guidance of $3.00 to $3.30. This show of confidence in the face of broader economic uncertainties likely contributed to the stock's after-hours rally. Additionally, the company's strong performance in its US Spine business, which grew 5.7% as reported and 7.4% on a day-adjusted basis, further bolstered investor optimism. The integration of the recently acquired Nevro is also progressing well, contributing to overall sales growth.